menu
    • menu
    [{"orgOrder":0,"company":"Micreos Human Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"XZ.700","moa":"Cell wall","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Micreos Human Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Micreos Human Health \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Micreos Human Health \/ Inapplicable"},{"orgOrder":0,"company":"Micreos Human Health","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Enzyme","year":"2022","type":"Financing","leadProduct":"XZ.700","moa":"Cell wall","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Micreos Human Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Micreos Human Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Micreos Human Health \/ Undisclosed"},{"orgOrder":0,"company":"Micreos Human Health","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Enzyme","year":"2021","type":"Funding","leadProduct":"XZ.700","moa":"Cell wall","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Micreos Human Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Micreos Human Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Micreos Human Health \/ Undisclosed"},{"orgOrder":0,"company":"Micreos Human Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"XZ.700","moa":"Cell wall","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Micreos Human Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Micreos Human Health \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Micreos Human Health \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Micreos Human Health

    Menu

    Micreos Human Health

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Micreos Human Health

                            Netherlands arrow
                            IFT FIRST
                            Not Confirmed

                            Micreos Human Health

                            Netherlands arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XZ.700

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Investigational Study Provides Evidence that Recombinant Endolysin XZ.700* Is a Promising Novel Non-Antibiotic...

                            Details : MEndoC (XZ.700) is a world-class endolysin platform, as a topical treatment of the inflammatory skin symptoms associated with CTCL. Studies have shown that aggressive antibiotic treatment inhibits proliferation of malignant T-cells and disease activity.

                            Product Name : XZ.700

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            July 03, 2023

                            Lead Product(s) : XZ.700

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Micreos Human Health

                            Netherlands arrow
                            IFT FIRST
                            Not Confirmed

                            Micreos Human Health

                            Netherlands arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XZ.700

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : $24.5 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Micreos’ Alternative to Antibiotics Secures Next €25 Million

                            Details : Proceeds includes the clinical development of XZ.700 for endolysins against staphylococci (including MRSA) for Bloodstream Infections, Atopic Dermatitis, Diabetic Foot Ulcers and Cutaneous T-cell Lymphoma, a type of skin cancer associated with presence o...

                            Product Name : XZ.700

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            October 25, 2022

                            Lead Product(s) : XZ.700

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : $24.5 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Micreos Human Health

                            Netherlands arrow
                            IFT FIRST
                            Not Confirmed

                            Micreos Human Health

                            Netherlands arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XZ.700

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : $37.1 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Micreos Secures €32 Million for Its Endolysin-Based Platform as Sustainable Alternative to Antibiotics

                            Details : This funding round will help Micreos accelerate its clinical development programs for atopic dermatitis, diabetic (MRSA) wounds and bloodstream infections, based on its pharmaceutical lead compounds, XZ.700 and SP.800.

                            Product Name : XZ.700

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            September 30, 2021

                            Lead Product(s) : XZ.700

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : $37.1 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Micreos Human Health

                            Netherlands arrow
                            IFT FIRST
                            Not Confirmed

                            Micreos Human Health

                            Netherlands arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XZ.700

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Micreos Initiates Clinical Trial to Evaluate World’s First Endolysin-Drug as a Therapy for Atopic Dermatitis

                            Details : Micreos Human Health has enrolled the first patients in a Phase I/IIa, randomized, double-blind, placebo-controlled, parallel treated dose-ranging study to assess the safety and efficacy of XZ.700 in patients with mild to moderate atopic dermatitis.

                            Product Name : XZ.700

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            September 22, 2020

                            Lead Product(s) : XZ.700

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth